학술논문
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF alpha inhibitor-experienced
Document Type
Journal
Author
Ritchlin, Christopher T.; Helliwell, Philip S.; Boehncke, Wolf-Henning; Soriano, Enrique R.; Hsia, Elizabeth C.; Kollmeier, Alexa P.; Chakravarty, Soumya D.; Zazzetti, Federico; Subramanian, Ramanand A.; Xu, Xie L.; Zuraw, Qing C.; Sheng, Shihong; Jiang, Yusang; Agarwal, Prasheen; Zhou, Bei; Zhuang, Yanli; Shawi, May; Karyekar, Chetan S.; Deodhar, Atul
Source
Subject
Language
English
ISSN
20565933